Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Icaritin Adjuvant Therapy for High-Risk HCC
NCT06644937Phase 3Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acoradine in hepatocellular carcinoma (HCC), sponsored by Southern Medical University Zhujiang Hospital. Started Nov 2024; status: recruiting.
02
Drugs
acoradine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06644937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644937.